• board | Enterprise Therapeutics | Treatment of respiratory diseases

Board

Amit Munshi

Amit Munshi

Chairman

Amit Munshi was most recently President and CEO of Arena Pharmaceuticals Inc. (Nasdaq:ARNA). He assumed the helm in 2016 and led the $300m market cap company through a turnaround process More...

Dr John Ford

Dr John Ford

Chief Executive Officer

John has more than 20 years’ experience building innovative and successful biotechnology companies. He co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (co-owner). More...

Dr Peter Finan

Dr Peter Finan

Investor Director

Pete Finan joined Epidarex in 2014. He has more than 20 years of experience in drug discovery within the pharmaceutical industry. More...

Bart Dzikowski

Bart Dzikowski

Investor Director, NVF

Bart Dzikowski is a Managing Director at the Novartis Venture Fund and its Head of Transactions & Legal based in Basel, Switzerland. He currently serves on the boards of Enterprise Therapeutics Holdings, More...

Dr Alex Mayweg

Dr Alex Mayweg

Investor Director

Alex is a Partner at Versant. Alex is an accomplished leader in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S. and Asia. More...

Dr Geert-Jan Mulder MD

Dr Geert-Jan Mulder MD

Investor Director

Geert-Jan Mulder co-founded Forbion in 2006 and serves as a Managing Partner for the fund and a Director on the board of ARMGO Pharma. Geert-Jan is an experienced life sciences investor More...

Craig Richardson

Craig Richardson

Investor Director

Craig Richardson is a Partner in IP Group’s Life Science investment team. He started his career in the pharmaceutical industry in 1998 and worked in new product development for Glaxo Wellcome, More...

Dr Rob Woodman

Dr Rob Woodman

Investor Director

Leading the Biotech team at Panakes Partners since 2021, Rob has global experience in biotech and pharma More...

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2020.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with compound currently in clinical trials.

Learn more